CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on engineered chimeric engulfment receptor T-cell, or CER-T, therapies targeting hematologic malignancies and solid tumors. The company became publicly traded in February 2024 through a business combination with Phoenix Biotech Acquisition Corp. (Nasdaq: PBAX), a blank-check company that completed its IPO in 2021 under the sponsorship of Phoenix Biotech Sponsor, LLC. Operating in the cell therapy and oncology sectors, CERO continues to file current reports with the SEC as a post-combination public company, including the Form 8-K submitted in July 2026. Sign up for full access on SpacDesk to explore complete deal data, sponsor profiles, and post-merger tracking for CERO and hundreds of other SPAC transactions.